Eli Lilly says neutralizing antibody cocktail nets significant reduction in COVID-19 hospitalizations, deaths

Drug maker Eli Lilly and Company today said its neutralizing antibodies cocktail of bamlanivimab and etesevimab combine to significantly reduce hospitalizations and deaths attributed to COVID-19.

Lilly said that based on results from a phase 3 clinical trial comprised of more than 1,000 patients it could conclude that the antibody cocktail reduced viral load and accelerated symptom resolution, resulting in zero deaths and just 11 hospitalizations.

Conversely, the placebo group experienced 10 deaths and 36 hospitalization.

The Lilly cocktail remains under consideration for an emergency use authorization from the Food and Drug Administration, the application for which was submitted in November.